Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.67 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.67 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.67 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.61 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.55 |
| ▸ | MYC | P01106 | 1/20 | 0.55 |
| ▸ | MAX | P61244 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7833539 | 0.96 | PLA2G4B (0.63) | AKR1C3AKR1C2AKR1C1PLA2G4BHCAR3 | |
| SCHEMBL3574447 | 0.93 | AKR1C3 (0.58) | AKR1C3AKR1C2AKR1C1PLA2G4BHCAR3 | |
| SCHEMBL7824920 | 0.89 | AKR1C3 (0.57) | AKR1C3AKR1C2AKR1C1PLA2G4BHCAR3 | |
| SCHEMBL1749792 | 0.89 | PLA2G4B (0.74) | AKR1C3AKR1C2AKR1C1PLA2G4BHCAR3 | |
| SCHEMBL22660921 | 0.88 | AKR1C3 (0.59) | AKR1C3AKR1C2AKR1C1PLA2G4BTHRA | |
| SCHEMBL3537490 | 0.87 | MAPT (0.62) | AKR1C3AKR1C2AKR1C1HCAR3MYC | |
| SCHEMBL222905 | 0.86 | AKR1C3 (0.61) | AKR1C3AKR1C2AKR1C1PLA2G4BTHRA | |
| SCHEMBL27403163 | 0.86 | PLA2G4B (0.74) | PLA2G4BHCAR3THRATHRBPRSS1 | |
| Hydrochloric Acid SCHEMBL3729179 | 0.86 | MAPT (0.60) | AKR1C3AKR1C2AKR1C1HCAR3MYC | |
| SCHEMBL28158589 | 0.85 | AKR1C3 (0.57) | AKR1C3AKR1C2AKR1C1TSHRTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106810463-A | Preparation method of oxybuprocaine hydrochloride | 沈阳绿洲制药有限责任公司 | 2017-06-09 | — | — | CN | claimed |
| CN-119735519-A | Method for improving clarity and color of solution in oxybuprocaine hydrochloride | 辰欣药业股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-106810463-A | Preparation method of oxybuprocaine hydrochloride | 沈阳绿洲制药有限责任公司 | 2017-06-09 | — | — | CN | disclosed |
| CN-106810463-A | Preparation method of oxybuprocaine hydrochloride | 沈阳绿洲制药有限责任公司 | 2017-06-09 | — | — | CN | disclosed |
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | disclosed |
| CN-102741257-B | Spiroindolinone pyrrolidines | HOFFMANN LA ROCHE | 2015-03-04 | — | — | CN | disclosed |
| CN-102741257-A | Spiroindolinone pyrrolidines | HOFFMANN LA ROCHE | 2012-10-17 | — | — | CN | disclosed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8088815-B2 | Spiroindolinone pyrrolidines | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011067185-A1 | SPIROINDOLINONE PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | BARTKOVITZ DAVID JOSEPH | 2011-06-02 | — | — | US | disclosed |
| US-4705861-A | AZO DYE CHEMICAL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 1987-11-10 | — | — | US | disclosed |
| US-4192947-A | REACTING DIAMINO NITROBENZENE WITH NITROBENZOYL CHLORIDE, CYCLIZING ANILIDE IN AQUEOUS ALKALI, REDUCING NITRO GROUPS WITH SULFIDE | CASSELLA AKTIENGESELLSCHAFT (DE) | 1980-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | RPS4Y1, RB1, RPS4X | AKR1C3 447/4885AKR1C2 400/4885AKR1C1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.